End-of-day quote
Other stock markets
|
||
- USD | - |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Sales 2019 | - | Sales 2020 | - | Capitalization | 551K 753K |
---|---|---|---|---|---|
Net income 2019 | - 0 | Net income 2020 | - 0 | EV / Sales 2019 | - |
Net Debt 2019 | 1.12M 1.53M | Net Debt 2020 | 874K 1.2M | EV / Sales 2020 | - |
P/E ratio 2019 |
3.09
x | P/E ratio 2020 |
-1.77
x | Employees | - |
Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 93.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 03-12-21 | |
James Grainer
CHM | Chairman | 69 | 20-05-21 |
Lois Chandler
COO | Chief Operating Officer | - | 10-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 03-12-21 | |
James Grainer
CHM | Chairman | 69 | 20-05-21 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 20-05-21 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |